A Decade in Review: A Systematic Review of Universal Influenza Vaccines in Clinical Trials during the 2010 Decade

OVX836 a recombinant nucleoprotein vaccine inducing cellular responses and protective efficacy against multiple influenza A subtypes

(2019) Judith Del Campo et al.   npj Vaccines

mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials

(2019) Robert A. Feldman et al.   VACCINE

Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial

(2019) David I Bernstein et al.   LANCET INFECTIOUS DISEASES

Influenza Infection in Humans Induces Broadly Cross-Reactive and Protective Neuraminidase-Reactive Antibodies

(2018) Yao-Qing Chen et al.   CELL

Annual estimates of the burden of seasonal influenza in the United States: A tool for strengthening influenza surveillance and preparedness

(2018) Melissa A. Rolfes et al.   Influenza and Other Respiratory Viruses

A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases

(2018) Emily J Erbelding et al.   JOURNAL OF INFECTIOUS DISEASES

Estimates of global seasonal influenza-associated respiratory mortality: a modelling study

(2018) A Danielle Iuliano et al.   LANCET

Prevalence of clinical trial status discrepancies: A cross-sectional study of 10,492 trials registered on both ClinicalTrials.gov and the European Union Clinical Trials Register

(2018) Jessica Fleminger et al.   PLoS One

Correlates of adjuvanticity: A review on adjuvants in licensed vaccines

(2018) Giuseppe Del Giudice et al.   SEMINARS IN IMMUNOLOGY

Novel influenza vaccine M2SR protects against drifted H1N1 and H3N2 influenza virus challenge in ferrets with pre-existing immunity

(2018) Yasuko Hatta et al.   VACCINE

Host Immune Response to Influenza A Virus Infection

(2018) Xiaoyong Chen et al.   Frontiers in Immunology

The Hurdles From Bench to Bedside in the Realization and Implementation of a Universal Influenza Vaccine

(2018) Sophie A. Valkenburg et al.   Frontiers in Immunology

Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults

(2018) L. Coughlan et al.   EBioMedicine

Nanoparticle Vaccines Against Infectious Diseases

(2018) Rashmirekha Pati et al.   Frontiers in Immunology

1947. Influenza Vaccination via Oral Tablet is Protective and Induces a Unique Mucosal Immune Response

(2018) Nikita Kolhatkar et al.   Open Forum Infectious Diseases

2554. Safety and Immunogenicity of NasoVAX, a Novel Intranasal Influenza Vaccine

(2018) Sybil Tasker et al.   Open Forum Infectious Diseases

Back to the future: Immunization with M-001 prior to trivalent influenza vaccine in 2011/12 enhanced protective immune responses against 2014/15 epidemic strain

(2017) George H. Lowell et al.   VACCINE

Stable emulsion (SE) alone is an effective adjuvant for a recombinant, baculovirus-expressed H5 influenza vaccine in healthy adults: A Phase 2 trial

(2017) John J. Treanor et al.   VACCINE

Vaccination with a Recombinant H7 Hemagglutinin-Based Influenza Virus Vaccine Induces Broadly Reactive Antibodies in Humans

(2017) Daniel Stadlbauer et al.   mSphere

Comparisons of the Humoral and Cellular Immune Responses Induced by Live Attenuated Influenza Vaccine and Inactivated Influenza Vaccine in Adults

(2016) Daniel F. Hoft et al.   Clinical and Vaccine Immunology

Global Role and Burden of Influenza in Pediatric Respiratory Hospitalizations, 1982–2012: A Systematic Analysis

(2016) Kathryn E. Lafond et al.   PLOS MEDICINE

Emerging influenza viruses and the prospect of a universal influenza virus vaccine

(2015) Florian Krammer   Biotechnology Journal

Meta-Analysis and Potential Role of Preexisting Heterosubtypic Cellular Immunity Based on Variations in Disease Severity Outcomes for Influenza Live Viral Challenges in Humans

(2015) Olga Pleguezuelos et al.   Clinical and Vaccine Immunology

A Synthetic Influenza Virus Vaccine Induces a Cellular Immune Response That Correlates with Reduction in Symptomatology and Virus Shedding in a Randomized Phase Ib Live-Virus Challenge in Humans

(2015) Olga Pleguezuelos et al.   Clinical and Vaccine Immunology

High titre neutralising antibodies to influenza after oral tablet immunisation: a phase 1, randomised, placebo-controlled trial

(2015) David Liebowitz et al.   LANCET INFECTIOUS DISEASES

Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection

(2015) Hadi M Yassine et al.   NATURE MEDICINE

A novel peptide-based pan-influenza A vaccine: A double blind, randomised clinical trial of immunogenicity and safety

(2015) James N. Francis et al.   VACCINE

Deaths averted by influenza vaccination in the U.S. during the seasons 2005/06 through 2013/14

(2015) Ivo M. Foppa et al.   VACCINE

Functions of the influenza A virus NS1 protein in antiviral defense

(2015) Robert M Krug   Current Opinion in Virology

Emerging influenza viruses and the prospect of a universal influenza virus vaccine

(2015) Florian Krammer   Biotechnology Journal

Impact of Influenza B Lineage-Level Mismatch Between Trivalent Seasonal Influenza Vaccines and Circulating Viruses, 1999–2012

(2014) Terho Heikkinen et al.   CLINICAL INFECTIOUS DISEASES

dsRNA-Activation of TLR3 and RLR Signaling: Gene Induction-Dependent and Independent Effects

(2014) Saurabh Chattopadhyay et al.   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

Priming by a novel universal influenza vaccine (Multimeric-001)—A gateway for improving immune response in the elderly population

(2014) Jacob Atsmon et al.   VACCINE

Nucleoprotein of influenza A virus is a major target of immunodominant CD8+ T-cell responses

(2013) Emma Grant et al.   IMMUNOLOGY AND CELL BIOLOGY

Estimating age-specific cumulative incidence for the 2009 influenza pandemic: a meta-analysis of A(H1N1)pdm09 serological studies from 19 countries

(2013) Maria D. Van Kerkhove et al.   Influenza and Other Respiratory Viruses

Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study

(2013) Marc Gurwith et al.   LANCET INFECTIOUS DISEASES

Clinical Assessment of a Novel Recombinant Simian Adenovirus ChAdOx1 as a Vectored Vaccine Expressing Conserved Influenza A Antigens

(2013) Richard D Antrobus et al.   MOLECULAR THERAPY

Coadministration of Seasonal Influenza Vaccine and MVA-NP+M1 Simultaneously Achieves Potent Humoral and Cell-Mediated Responses

(2013) Richard D Antrobus et al.   MOLECULAR THERAPY

Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies

(2013) Masaru Kanekiyo et al.   NATURE

Examination of Influenza Specific T Cell Responses after Influenza Virus Challenge in Individuals Vaccinated with MVA-NP+M1 Vaccine

(2013) Timothy J. Powell et al.   PLoS One

Phase I/II trial of a replication-deficient trivalent influenza virus vaccine lacking NS1

(2013) Christina Mössler et al.   VACCINE

Mechanisms of Action of Adjuvants

(2013) Sunita Awate et al.   Frontiers in Immunology

Recombinant vaccines and the development of new vaccine strategies

(2012) I.P. Nascimento et al.   BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH

Preliminary Assessment of the Efficacy of a T-Cell–Based Influenza Vaccine, MVA-NP+M1, in Humans

(2012) Patrick J. Lillie et al.   CLINICAL INFECTIOUS DISEASES

Safety and Immunogenicity of Multimeric-001—a Novel Universal Influenza Vaccine

(2012) Jacob Atsmon et al.   JOURNAL OF CLINICAL IMMUNOLOGY

A T Cell-Inducing Influenza Vaccine for the Elderly: Safety and Immunogenicity of MVA-NP+M1 in Adults Aged over 50 Years

(2012) Richard D. Antrobus et al.   PLoS One

Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response

(2012) David N. Taylor et al.   VACCINE

Synthetic Influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled Phase I trial

(2012) Olga Pleguezuelos et al.   VACCINE

Advax™, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses

(2012) Yoshikazu Honda-Okubo et al.   VACCINE

Safety and Immunogenicity of a Plant-Produced Recombinant Hemagglutinin-Based Influenza Vaccine (HAI-05) Derived from A/Indonesia/05/2005 (H5N1) Influenza Virus: A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study in Healthy Adults

(2012) Jessica Chichester et al.   Viruses-Basel

Vaccinate for the next H2N2 pandemic now

(2011) Gary J. Nabel et al.   NATURE

Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza–flagellin fusion vaccine (VAX125, STF2.HA1 SI)

(2011) David N. Taylor et al.   VACCINE

Ferritin in the field of nanodevices

(2010) Ichiro Yamashita et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

Toll-Like Receptor Agonists

(2010) Sacha Gnjatic et al.   CANCER JOURNAL

Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA-NP+M1

(2010) T. K. Berthoud et al.   CLINICAL INFECTIOUS DISEASES

Superior efficacy of a recombinant flagellin:H5N1 HA globular head vaccine is determined by the placement of the globular head within flagellin

(2009) Langzhou Song et al.   VACCINE